Participated · Equity · Sep 2024

Pieces Technologies builds cloud-based clinical generative AI and ensemble-AI solutions to support inpatient care teams and streamline clinician workflows. The company applies applied clinical generative AI, adversarial and collaborative AI, predictive modeling, and physician-supervised machine learning to improve patient, financial, and operational outcomes. Led by CEO Ruben Amarasingham, Pieces specializes in generating inpatient clinical summaries and other clinician-facing tools for health systems. As of September 10, 2024, the company has generated more than 5.4 million inpatient clinical summaries across multiple health system clients. Pieces intends to use new funding to deploy its AI-driven solutions nationwide. The company is headquartered in Dallas, TX. Pieces Technologies develops healthcare artificial intelligence and technology to link health systems with community organizations for addressing clinical and social determinants of health. Its core products are the Pieces Decision Sciences (DS) clinical analytics engine and the Pieces Iris® social determinants of health (SDoH) platform. Since 2016, Pieces has been building integrated communities between health systems and community service providers. Its clients include hospitals, health systems, health plans, community health clinics and community service providers such as food banks, job assistance and educational services. In January 2020 the company closed a $25.7 million Series B to accelerate national distribution of its Decision Sciences and Iris platforms. Pieces Technologies develops the Pieces™ software platform, a predictive, cloud-based health information technology that offers integrated monitoring, prediction, workflow optimization, and organizational learning for hospitals, health systems, and community-based organizations. The platform interprets patient data in real time using predictive models and clinical research to create warning tools intended to identify and prevent adverse events such as avoidable mortality and re-hospitalization. Pieces Tech also provides cloud-based software for community organizations to manage client needs and connects to hospital information systems to offer a holistic view of patients. The Pieces™ platform was incubated at the Parkland Center for Clinical Innovation, and Parkland has reported benefits from its use. Children’s Health is working with Pieces to advance and co-develop technology for earlier interventions in pediatric chronic conditions. Founder and CEO Ruben Amarasingham, M.D., leads the company as it readies for broader marketplace expansion following its Series A financing.

Participated · Series C · May 2021

Piano offers an end-to-end digital experience platform that combines data architectures, AI, and commerce features to help brands and publishers identify, understand, and serve customers at scale with privacy compliance. Its platform is designed to operate at massive scale and deliver audience experiences faster than competing solutions. The company serves global, national, and local brands across six continents and maintains more than 15 offices, with U.S. headquarters in Philadelphia. Piano was founded in 2010 and has been recognized by Red Herring, the World Economic Forum, and Deloitte for its growth and innovation. The company intends to use new capital to enhance platform capabilities, expand market presence, and support strategic growth initiatives. The articles do not disclose revenue or user metrics. Piano builds analytics, subscription and personalization tools for publishers, combining paywall and subscription management with content analytics and audience-engagement features. The company works with around 1,000 customers, including CNBC, Wall Street Journal, The Economist and TechCrunch. Revenues have grown 400% since 2019 and Piano is operating at roughly a $75M annual run rate. It acquired French analytics firm AT Internet in March to better integrate cross-silo traffic, advertising, subscription and engagement data. Piano plans to expand into newsletter products and other audience-connection areas, and may pursue further M&A to consolidate fragmented capabilities. The company will use new funding to continue building its technology and to explore integrations with strategic partners. Piano provides a monetization and audience intelligence technology platform that includes a subscription commerce engine, a customer experience toolkit, and a user management system. The company serves more than a thousand premium media brands, including Business Insider, The Economist, Bloomberg, Men’s Health, AdAge, Digiday and The Chive. Led by CEO Trevor Kaufman and based in New York City, Piano employs about 180 staff across seven offices from New York and London to Rio De Janeiro. The company raised $22M in a Series B to fund continued product and service enhancements and to grow across functions, particularly R&D and client services. Piano plans to expand into new markets and sectors and is considering several acquisitions. Tinypass provides an e-commerce platform that lets content creators and publishers monetize digital content with paywalls, downloads and a variety of pricing, access and subscription options. The platform integrates with publishers' existing site infrastructure and content management systems, is free to set up, and scales from individual bloggers to multi-national publications. Tinypass reports high conversion rates across its publisher base and says it has been growing at roughly 40% month-to-month since the beginning of the year. Its client roster includes major media companies, local newspapers, online education providers, health and wellness sites, business information providers and research organizations. The company closed a $3 million financing round led by Cascabel Management and Plough Penny Partners, after previously raising $1.25 million in seed financing in 2012. Tinypass has also added senior hires — a COO, CTO and an EVP of sales & business development — which it frames as the next step in its mission to simplify digital content monetization.

Led · Series B · Aug 2020

Cecelia Health is a NYC-based technology-enabled company that provides coaching and telemedicine services for diabetes and other chronic diseases. Its core product is a digital health platform staffed by expert clinicians—CDCESs and endocrinologists—that supports remote patient care and chronic disease management. The company has logged over one million remote patient interactions, reflecting significant usage of its telehealth services. Cecelia plans to expand its digital health capabilities and scale adoption of its technology-enabled coaching and telemedicine solutions using the new capital. It intends to launch a commercial Virtual Clinic that will provide CGM training, medication-adherence education, lifestyle and behavior-change support, and mental-health screening and counseling. Algorithms will recommend dosage and titration changes that are reviewed and approved by Cecelia’s clinicians, and the Virtual Clinic will be supported by a national network of diabetes professionals. Fit4D is a NYC-based diabetes management technology services company that provides a patient-centric, technology-enabled coaching solution. Led by CEO David Weingard, its purpose-built coaching platform enables Certified Diabetes Educator (CDE) clinicians to scale their reach and deliver personalized, one-on-one diabetes management programs through an optimized mix of humans and technology. The Fit4D clinical team is comprised primarily of CDEs with clinical credentials such as nurses, registered dietitians, pharmacists, exercise physiologists and social workers. The company partners with health plans and providers and has engaged in joint initiatives with the Juvenile Diabetes Research Foundation, the American Diabetes Association, the Diabetes Research Institute and the American Association of Diabetes Educators. In April 2018 the company raised $4M in expansion financing and intends to use the funds to consolidate its market position. Fit4D is a NYC-based digital health company focused on people living with diabetes, delivering patient programs through a combination of a technology platform and human-based touch points. Its clinical team includes dietitians, exercise physiologists, nurses, social workers, and many certified diabetes educators (CDEs) who provide personalized care. The platform supports electronic interactions in patient-preferred modalities (phone, email, text, web, video) and delivers content in preferred formats and at preferred times to address patient-specific issues. Clients include pharmaceutical companies, payers, providers and wellness companies. Fit4D secured a Series A of undisclosed amount backed by SJF Ventures, Sovereign Health System and Blue Cross and Blue Shield of Nebraska. The company intends to use the funds to expand distribution across new customer channels and to leverage the platform to improve health outcomes for other chronic diseases; it is led by CEO David Weingard and is a member of the StartUp Health Academy.

Participated · Series C · Mar 2020

VIDA offers the VIDA Intelligence Portal, an AI-powered platform that supports clinical trial decentralization and improves site recruitment, onboarding, staff training, image data management and data quality. Five months after launching the Portal, demand expanded VIDA’s network to more than 1,000 sites and drove substantial increases in bookings and annual recurring revenue. The company also markets VIDA Insights, a complementary data-driven solution authorized for use in Japan in April 2022 to aid lung care teams at the point of care. VIDA is using product and commercial momentum to accelerate innovation and broader adoption in the biopharma market for clinical data intelligence. Leadership additions and planned strategic senior hires are intended to support rapid commercial growth and operational scale. The company is actively showcasing its solutions at industry conferences to drive awareness and adoption. Vida Diagnostics develops AI-powered CT imaging software and services to aid early detection, evaluation and treatment planning for patients with or at risk of respiratory and lung diseases. Led by CEO Susan A. Wood, Ph.D., the company targets conditions including emphysema, COPD, asthma, interstitial lung disease and lung cancer. Its software and services are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, EEA, Canada and Australia. Vida plans to use the funds to accelerate development and commercialization of its solutions and to impact patient care for both traditional respiratory diseases and emergent COVID-19 conditions. The company received a $2M second close from OSF Ventures that augmented an $11M tranche announced the prior month, completing a $13M Series C funding round. Based in Coraville, Iowa, Vida is focusing on broader commercial adoption of its AI imaging solutions. Vida Diagnostics develops AI-powered CT imaging software and services to aid early detection, evaluation, and treatment planning for patients with or at risk of lung diseases. Its core product is the LungPrint® solution suite, which the company plans to commercialize more broadly and expand clinically. The company raised an $11M initial close of its Series C financing to accelerate commercialization and expand LungPrint’s clinical portfolio. Vida’s offerings are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use. The technology targets conditions including emphysema, COPD, asthma, interstitial lung disease and lung cancer. The company is led by Susan A. Wood, Ph.D., CEO. Vida Diagnostics develops AI-powered lung analysis software called LungPrint, a fully automated analysis of inspiratory chest CT scans that flags lung density abnormalities indicative of emphysema or interstitial lung disease. The company positions its solution to improve patient outcomes, elevate quality of care, and lower overall health care costs by addressing the growing burden of pulmonary disease. Vida entered a strategic partnership with UnityPoint Health Ventures to develop and commercialize LungPrint and drive adoption across clinical settings. The partnership grants Vida access to UnityPoint Health’s multi-state network of hospitals and clinics and to clinical experts who will inform the company’s product roadmap and commercialization efforts. Vida also secured non-dilutive funding from the Iowa Economic Development Authority. The company is led by CEO Susan A. Wood, Ph.D., and is based in Coralville, Iowa. Vida Diagnostics offers a lung informatics solution that combines image analysis services (Precision Services) with software visualization and analytics (VIDA|vision). The product suite spans diagnostic and therapeutic planning applications for pulmonary disease management. VIDA|vision provides airway mapping software to guide bronchoscopic biopsy for suspected lung cancer and delivers advanced, clinically-validated measures to inform treatment selection for severe emphysema patients. The company serves clinicians treating lung cancer, COPD, and asthma. Vida intends to use the financing to hire additional personnel and enhance its clinical software and services. The company is led by President and CEO Susan A. Wood, Ph.D., and also maintains an office in Minneapolis, MN.

Participated · Equity · Sep 2016

WealthHub Solutions offers a cloud-based platform for trust officers and other fiduciaries that integrates investment data and reporting with automated workflow, client management and prospecting, task scheduling, document management and compliance. The company has been selling its product for one year to U.S. trust companies, family offices and law firms and currently serves 12 clients with many more prospects. WealthHub is two years old and was founded by Antony Joffe. The business is based in Conshohocken and shares an office building with Sterling Trustees, which is the largest shareholder. Management says the company will use new financing to accelerate growth, expand product development, and support sales and marketing, including hiring additional sales professionals. Leadership includes CEO Jim Marks and investors include institutional backers and individual investors such as Tom Petro.